Lim S, Oh TJ, Dawson J, et al. - Since people with diabetes mellitus are at higher risk of ischemic stroke and worse outcomes, researchers provided an overview of the effectiveness of intensive vs conventional glucose-lowering treatment in post-stroke management. Investigators found that pioglitazone and the glucagon-like peptide-1 receptor agonist class (other than short-acting lixisenatide or oral semaglutide) have greater odds of lowering the incidence of cerebrovascular disease (mechanisms not based on glucose-reduction per se); there is no consistent evidence for other classes of drug.